Canaccord raised the firm’s price target on Clover Health (CLOV) to $4.50 from $4.20 and keeps a Buy rating on the shares. The rim said following the Q4 report they remain optimistic about the company’s opportunity going forward. For Clover, the year that was just put to bed was monumental, but more importantly Canaccord believes the outlook for additional accomplishments looks promising for several years to come.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLOV:
- Clover Health’s Earnings Call Highlights Profitability and Growth
- Clover Health Investments: Strong Financial Turnaround and Strategic Growth Drive Buy Rating
- Clover Health Reports Improved 2024 Financial Results
- Clover Health reports Q4 EPS (4c), consensus (6c)
- Clover Health options imply 9.0% move in share price post-earnings